脓毒血症的病理机制、诊断与治疗进展

金 群1, 石 展鹰1, 陈 琴琴1, 梁 伟*2
1、第九〇六医院检验科
2、宁波大学附属第一医院检验科

摘要


脓毒血症是一种由感染触发的全身性炎症反应综合症（Systemic Inflammatory Response Syndrome，SIRS），其主要特点包括免疫系统的混乱、凝血机制的障碍以及多个器官功能的衰退。在全球范围内，每年大约新发4700-5000万的病例，病死率高达20%。本文围绕脓毒症这一主题，涵盖了脓毒症的病理机制、用于诊断的标志物以及相关治疗策略的发展情况。在此基础上，对该病症的病理机制、诊断和治疗的最新进展做出了新的阐述。

关键词


脓毒血症；机制；治疗进展

全文:

PDF


参考


[1]Fu X, Liu Z, Wang Y. Advances in the Study of Immunosuppressive Mechanisms in Sepsis[J]. Journal of Inflammation Research, 2023, 16: 3967-3981.

[2]Sungurlu S, Kuppy J, Balk R A. Role of Antithrombin III and Tissue Factor Pathway in the Pathogenesis of Sepsis[J]. Critical Care Clinics, 2020, 36(2): 255-265.

[3]Gong H, Chen Y, Chen M, Li J, Zhang H, Yan S, Lv C. Advanced development and mechanism of sepsis-related acute respiratory distress syndrome[J]. Frontiers in Medicine, 2022, 9: 1043859.

[4]张恺，张根生.脓毒症患者死亡风险预测模型及评分的构建和评价[D]//浙江大学.浙江大学，2020.

[5]赵赫，刘红梅，朱志华，田莉.脓毒症休克患者SOFA评分、APACHEⅡ评分、RDW、RPR、血乳酸水平变化及意义分析[J].中国急救复苏与灾害医学杂志，2025，20（05）：632-636.

[6]Chen M, Zhu Y. Utility of sTREM-1 and Presepsin (sCD14-ST) as Diagnostic and Prognostic Markers of Sepsis[J]. Clinical Laboratory, 2020, 66(4).

[7]Yin W-P, Li J-B, Zheng X-F, An L, Shao H, Li C-S. Effect of neutrophil CD64 for diagnosing sepsis in emergency department[J]. World Journal of Emergency Medicine, 2020, 11(2): 79-86.

[8]Pham H M, Nguyen D L M, Duong M C, Phan X T, Tran L T, Trang D H T, Pham T T N. Neutrophil CD64-a prognostic marker of sepsis in intensive care unit: a prospective cohort study[J]. Frontiers in Medicine, 2023, 10: 1251221.

[9]Simm M, Söderberg E, Larsson A, Castegren M, Nilsen T, Eriksson M, Lipcsey M. Performance of plasma calprotectin as a biomarker of early sepsis: a pilot study[J]. Biomarkers in Medicine, 2016, 10(8): 811-818.

[10]Htay H, Gow S K, Jayaballa M, Oei E L, Chan C-M, Wu S-Y, Foo M W. Preliminary safety study of the Automated Wearable Artificial Kidney (AWAK) in Peritoneal Dialysis patients[J]. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2022, 42(4): 394-402.

[11]Bi C-F, Liu J, Hao S-W, Xu Z-X, Ma X, Kang X-F, Yang L-S, Zhang J-F. Xuebijing injection protects against sepsis-induced myocardial injury by regulating apoptosis and autophagy via mediation of PI3K/AKT/mTOR signaling pathway in rats[J]. Aging, 2023, 15(10): 4374-4390.

[12]François B, Wittebole X, Ferrer R, Mira J-P, Dugernier T, Gibot S, Derive M, Olivier A, Cuvier V, Witte S, Pickkers P, Vandenhende F, Garaud J-J, Sánchez M, Salcedo-Magguilli M, Laterre P-F. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial[J]. Intensive Care Medicine, 2020, 46(7): 1425-1437.

[13]陈锦笛，董晓斌.清瘟败毒饮对脓毒症凝血指标影响的研究[D]//山东中医药大学.山东中医药大学.

[14]François B, Wittebole X, Ferrer R, Mira J-P, Dugernier T, Gibot S, Derive M, Olivier A, Cuvier V, Witte S, Pickkers P, Vandenhende F, Garaud J-J, Sánchez M, Salcedo-Magguilli M, Laterre P-F. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial[J]. Intensive Care Medicine, 2020, 46(7): 1425-1437. , 2020.

[15]Deniau B, Takagi K, Asakage A, Mebazaa A. Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis[J]. Expert Opinion on Investigational Drugs, 2021, 30(2): 95-102.


Refbacks

  • 当前没有refback。